Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety Outcomes of CAR T-Cell Therapies in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Who Received Prior Treatment with Mosunetuzumab

Adam Braun, Stephen J. Schuster, Loretta Nastoupil, Nancy L. Bartlett, Mazyar Shadman, Anita Kumar, Dimitrios Tzachanis, Dai Chihara, Mei Wu, Michael C. Wei, Shen Yin, Jing Qi Hao, Qian Zhu, Yong Mun, L. Elizabeth Budde

Blood (2024) 144 (Supplement 1): 6555.

https://doi.org/10.1182/blood-2024-198409

Published: 2024

Journal Articles

Mosunetuzumab is Cost-Effective Compared with Alternative Novel Treatment Options in Patients with Third-Line or Later Relapsed/Refractory Follicular Lymphoma Over a Long-Term Horizon in the United States

Matthew Matasar, Katherine L Rosettie, Almut Mecke, Danilo Di Maio, Shih-Wen Lin, Mei Wu, Esprit Ma

Blood (2024) 144 (Supplement 1): 3648.

https://doi.org/10.1182/blood-2024-198657

Published: 2024

Journal Articles

Lower Total Cost of Care with Mosunetuzumab Compared with Alternative Novel Treatment Options in Third-Line or Later Relapsed/Refractory Follicular Lymphoma: A United States Third-Party Payer Perspective

Matthew Matasar, Katherine L Rosettie, Shih-Wen Lin, Mei Wu, Esprit Ma

Blood (2024) 144 (Supplement 1): 5029.

https://doi.org/10.1182/blood-2024-198660

Published: 2024

Journal Articles

Fixed-Duration Subcutaneous Mosunetuzumab Is Active and Has a Manageable Safety Profile in Patients with Previously Untreated, Low-Tumor Burden Follicular Lymphoma: Updated Results from the Phase II Morningsun Study

John M. Burke, Ian W. Flinn, L. Elizabeth Budde, Aung M. Tun, Steven Liu, Juliana M.L. Biondo, Prachi Jani, Mei Wu, Yong Mun, Vivek S. Chopra, Jessica M. Grindheim, Dana Farinella, Jose C. Villasboas Bisneto

Blood (2024) 144 (Supplement 1): 3008.

https://doi.org/10.1182/blood-2024-194604

Published: 2024

Journal Articles

Travel Burden and Travel Costs of Bispecific Antibodies in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Relapsed/Refractory Follicular Lymphoma

Scott F Huntington, Anthony Masaquel, Esprit Ma, Eric Zuk, Hélène Parisé, Matthew Davis, David Fox, Fadoua El Moustaid, Arliene Mangalindan, Lourenia Cassoli, Mei Wu, Zachary AK Frosch

Blood (2024) 144 (Supplement 1): 782.

https://doi.org/10.1182/blood-2024-198414

Published: 2024

Journal Articles

Subcutaneous Mosunetuzumab Is Active and Has a Manageable Safety Profile in Patients with Previously Untreated, Low-Tumor Burden Follicular Lymphoma: Initial Results from the Phase II Morningsun Study

Ian W. Flinn, L. Elizabeth Budde, Aung M. Tun, John M. Burke, Bertrand Anz, Shachar Peles, Jeff P. Sharman, Praveen K. Tumula, Juliana M. L. Biondo, Prachi Jani, Mei Wu, Tony Lin, Neha Parmar, Yong Mun, Nai-Shun Yao, Steven Liu

Blood (2023) 142 (Supplement 1): 3029.

https://doi.org/10.1182/blood-2023-177917

Published: 2023

Journal Articles

Response to Mosunetuzumab in Patients with B-Cell Lymphomas Relapsed or Refractory after CAR-T Cell Therapy Is Associated with Changes in Lymphocyte Counts

Elise A. Chong, Elicia Penuel, Nancy L. Bartlett, Francesc Bosch, L. Elizabeth Budde, Keith Fay, Ian W. Flinn, Andre Goy, Anita Kumar, Rachel Lundberg, Ellen B. Napier, Loretta J. Nastoupil, Mazyar Shadman, Michael C. Wei, Mei Wu, Shen Yin, Emeline R. Chong, Stephen J. Schuster

Blood (2023) 142 (Supplement 1): 1752.

https://doi.org/10.1182/blood-2023-190201

Published: 2023

Journal Articles

Anti-PD-1 Antibody (Tislelizumab) Combined with R-CHOP for the Treatment of Previously Untreated Primary Mediastinal B-Cell Lymphoma: A Prospective Phase II Study

Mei Wu, Lin Zhu, Shan Li, Tuerde Jiaerbao, Shanshan Wang, Xiao Liang, Xin Hu, Li Guo, Abulikemujiang Adili, Xianmusiya Maimaitirexiati, Ruirui Ren, Zhihua Yao, Shuna Yao, Shujuan Wen

Blood (2023) 142 (Supplement 1): 6236.

https://doi.org/10.1182/blood-2023-182504

Published: 2023

Journal Articles

Treatment Patterns and Outcomes Among Patients with Relapsed/Refractory Follicular Lymphoma Treated in Routine Clinical Practice in the US with Three or More Lines of Therapy

Jamie T. Ta, Stella Arndorfer, Cristina Julian, Mei Wu, Dominic Lai, Sheila Shapouri

Blood (2021) 138 (Supplement 1): 4080.

https://doi.org/10.1182/blood-2021-145412

Published: 2021

Journal Articles

Healthcare Resource Utilization and Costs of Patients with Relapsed/Refractory Follicular Lymphoma Receiving 3 or More Lines of Therapy

Matthew J. Matasar, Sheila Shapouri, Jamie T. Ta, Tu My To, Mei Wu, Rongrong Wang

Blood (2021) 138 (Supplement 1): 1923.

https://doi.org/10.1182/blood-2021-145407

Published: 2021

Journal Articles

Discontinuation Patterns in Patients Receiving Novel Oral Agents for Chronic Lymphocytic Leukemia in the Veterans Health Administration

Hsu-Chih Chien, PhD MSc, Vikas Patil, MS, Kelli M Rasmussen, MS, Christina Yong, MA, Juliana M L Biondo, MD, Mary Halloran, PharmD, BCPS, Sheila Shapouri, PharmD, MS, Mei Wu, PharmD, Zachary R Burningham, PhD, Brian C Sauer, PhD, Ahmad S Halwani, MD

Blood (2019) 134 (Supplement_1): 4309.

https://doi.org/10.1182/blood-2019-128645

Published: 2019

Journal Articles

c-Myb acts in parallel and cooperatively with Cebp1 to regulate neutrophil maturation in zebrafish

Hao Jin, Zhibin Huang, Yali Chi, Mei Wu, Riyang Zhou, Lingfeng Zhao, Jin Xu, Fenghua Zhen, Yahui Lan, Li Li, Wenqing Zhang, Zilong Wen, Yiyue Zhang

Blood (2016) 128 (3): 415–426.

https://doi.org/10.1182/blood-2015-12-686147

Published: 2016

Includes: Supplemental data

Journal Articles

A topological study of the human γ-glutamyl carboxylase

Jianke Tie, Sheue-Mei Wu, Dayun Jin, Christopher V. Nicchitta, Darrel W. Stafford

Blood (2000) 96 (3): 973–978.

https://doi.org/10.1182/blood.V96.3.973

Published: 2000

Journal Articles

A Missense Mutation in γ-Glutamyl Carboxylase Gene Causes Combined Deficiency of All Vitamin K-Dependent Blood Coagulation Factors

Benjamin Brenner, Beatriz Sánchez-Vega, Sheue-Mei Wu, Naomi Lanir, Darrel W. Stafford, Jesus Solera

Blood (1998) 92 (12): 4554–4559.

https://doi.org/10.1182/blood.V92.12.4554

Published: 1998

Journal Articles

Genomic Sequence and Transcription Start Site for the Human γ-Glutamyl Carboxylase

Sheue-Mei Wu, Darrel W. Stafford, L. Dan Frazier, Yuan-Yun Fu, Katherine A. High, Kirk Chu, Beatriz Sanchez-Vega, Jesús Solera

Blood (1997) 89 (11): 4058–4062.

https://doi.org/10.1182/blood.V89.11.4058

Published: 1997

NARROW

Efficacy and Safety Outcomes of CAR T-Cell Therapies in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Who Received Prior Treatment with Mosunetuzumab

Mosunetuzumab is Cost-Effective Compared with Alternative Novel Treatment Options in Patients with Third-Line or Later Relapsed/Refractory Follicular Lymphoma Over a Long-Term Horizon in the United States

Lower Total Cost of Care with Mosunetuzumab Compared with Alternative Novel Treatment Options in Third-Line or Later Relapsed/Refractory Follicular Lymphoma: A United States Third-Party Payer Perspective

Fixed-Duration Subcutaneous Mosunetuzumab Is Active and Has a Manageable Safety Profile in Patients with Previously Untreated, Low-Tumor Burden Follicular Lymphoma: Updated Results from the Phase II Morningsun Study

Travel Burden and Travel Costs of Bispecific Antibodies in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Relapsed/Refractory Follicular Lymphoma

Subcutaneous Mosunetuzumab Is Active and Has a Manageable Safety Profile in Patients with Previously Untreated, Low-Tumor Burden Follicular Lymphoma: Initial Results from the Phase II Morningsun Study

Response to Mosunetuzumab in Patients with B-Cell Lymphomas Relapsed or Refractory after CAR-T Cell Therapy Is Associated with Changes in Lymphocyte Counts

Anti-PD-1 Antibody (Tislelizumab) Combined with R-CHOP for the Treatment of Previously Untreated Primary Mediastinal B-Cell Lymphoma: A Prospective Phase II Study

Treatment Patterns and Outcomes Among Patients with Relapsed/Refractory Follicular Lymphoma Treated in Routine Clinical Practice in the US with Three or More Lines of Therapy

Healthcare Resource Utilization and Costs of Patients with Relapsed/Refractory Follicular Lymphoma Receiving 3 or More Lines of Therapy

Discontinuation Patterns in Patients Receiving Novel Oral Agents for Chronic Lymphocytic Leukemia in the Veterans Health Administration

c-Myb acts in parallel and cooperatively with Cebp1 to regulate neutrophil maturation in zebrafish

A topological study of the human γ-glutamyl carboxylase

A Missense Mutation in γ-Glutamyl Carboxylase Gene Causes Combined Deficiency of All Vitamin K-Dependent Blood Coagulation Factors

Genomic Sequence and Transcription Start Site for the Human γ-Glutamyl Carboxylase

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only